Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) shares saw an uptick in trading volume on Wednesday . 106,601 shares were traded during trading, a decline of 45% from the previous session’s volume of 195,283 shares.The stock last traded at $21.00 and had previously closed at $20.98.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on RAPP. TD Cowen initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They set a “buy” rating on the stock. Stifel Nicolaus initiated coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective on the stock. Finally, Jefferies Financial Group assumed coverage on shares of Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating and a $35.00 price objective on the stock.
Get Our Latest Report on Rapport Therapeutics
Rapport Therapeutics Trading Up 8.3 %
Insider Buying and Selling
Rapport Therapeutics Company Profile
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Recommended Stories
- Five stocks we like better than Rapport Therapeutics
- Transportation Stocks Investing
- Joby Aviation Stock: The Case for Upside Just Got Stronger
- How is Compound Interest Calculated?
- Conviction Firms for Microsoft’s Double-Digit Stock Upside
- What is a Bond Market Holiday? How to Invest and Trade
- 5 Aggressive Growth Stocks for Long-Term Investors
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.